Results 231 to 240 of about 2,060,350 (286)

Cell cycle arrest enhances CD8⁺ T cell effector function by potentiating glucose metabolism and IL-2 signaling. [PDF]

Nat Immunol
van Haften FJ, van der Sluis TC, Hepp HS, Mülling N, Nadafi R, Sampadi B, van Duikeren S, Mostert JS, van der Sterre R, van Veelen PA, Heieis GA, Veerkamp DMB, Wesselink TH, Vleeshouwers W, Beijnes M, Pardieck IN, van Horssen ELF, de Groot AF, van der Ploeg M, Kroep JR, de Miranda NFCC, van der Zanden SY, Neefjes J, Mei H, Vertegaal ACO, Everts B, van der Burg SH, Arens R.   +27 more
europepmc   +1 more source

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source

IL-2 and IL-7 Contribution to Immune Response: Effects of Vaccination Against COVID-19 in Adults. [PDF]

Viruses
Siedlecka D, Bielawska L, Ludziejewska A, Baszczuk A, Wysocka E.   +4 more
europepmc   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. [PDF]

Cell Rep Med
Ahn JJ, Dudics S, Langan DP, Smith JD, Hsu AH, McCright JC, Smith SR, Castleberry AL, George BI, Goitía Vázquez JA, Kuri PN, Alla SSV, Garcia J, Haider YM, Hamdan FW, Juárez JE, Reddy R, Shanmuganathan A, Wang Y, Welch A, Boclair D, Khrimian PA, Yaen CH, Mumm JB.   +23 more
europepmc   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

A CD4+ T lymphocyte-specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity. [PDF]

J Clin Invest
Yao Y, Wang L, Jiang W, Wang N, Li M, Lin W, Zhang T, Sheng W, Wang X.   +8 more
europepmc   +1 more source

EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

Molecular Oncology, EarlyView.
Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau, Leonor Garcia, Hugo Arnold, Antonija Hanžek, Maialen Arrieta, Laurent R Gauthier, Christine Granotier‐Beckers, François D Boussin, Amaury Herbet, Marie Hautière, Valentin Asei‐Ceschino, Clémentin Jacques, Laura Brard, Thomas Harnois, Valérie Coronas, Bruno Constantin, Aurélien Chatelier, Jean Chemin, Serge Urbach, Martial Seveno, Szimonetta Hideg, Chantal Ripoll, Kasandra Aguilar‐Cázarez, Min Zheng, Guo‐Hao Huang, Sheng‐Qing Lv, Lei Zhang, Philippe Rondard, Laurent Prezeau, Jean‐Philippe Pin, Hugues Duffau, Luc Bauchet, Valérie Rigau, Franck Denat, Charles Truillet, Didier Boquet, Jean‐Philippe Hugnot   +36 more
wiley   +1 more source

DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. [PDF]

Cell Rep Med
Stockmann AP, Vincent S, Herschelman L, Huang CS, Ma J, Fallon D, Kirby P, Gutierrez E, Talbot D, Hicks SW, Wagtmann N, Cheung AF.   +11 more
europepmc   +1 more source